Research Analysts Offer Predictions for Ovid Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:OVID)

Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Equities researchers at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a research report issued to clients and investors on Tuesday, May 14th. Wedbush analyst L. Chico forecasts that the company will post earnings of ($0.24) per share for the quarter. Wedbush has a "Outperform" rating and a $8.00 price objective on the stock. The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.73) per share. Wedbush also issued estimates for Ovid Therapeutics' Q4 2025 earnings at ($0.20) EPS.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last released its earnings results on Friday, March 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05). The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.10 million. Ovid Therapeutics had a negative net margin of 13,351.53% and a negative return on equity of 49.76%.

OVID has been the topic of a number of other research reports. B. Riley initiated coverage on Ovid Therapeutics in a report on Tuesday, April 30th. They issued a "buy" rating and a $9.00 target price on the stock. Citigroup reduced their price objective on Ovid Therapeutics from $4.00 to $3.50 and set a "neutral" rating on the stock in a research note on Tuesday, May 7th. Finally, HC Wainwright started coverage on Ovid Therapeutics in a research note on Monday, April 29th. They set a "buy" rating and a $9.00 target price for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $8.08.

Ovid Therapeutics Price Performance

NASDAQ:OVID traded up $0.09 during mid-day trading on Wednesday, reaching $3.32. The stock had a trading volume of 155,028 shares, compared to its average volume of 184,362. Ovid Therapeutics has a 12 month low of $2.57 and a 12 month high of $4.14. The stock has a market capitalization of $235.09 million, a PE ratio of -4.43 and a beta of 0.69. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.55 and a quick ratio of 9.55. The stock has a 50-day simple moving average of $3.07 and a two-hundred day simple moving average of $3.30.

Hedge Funds Weigh In On Ovid Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new stake in Ovid Therapeutics during the 4th quarter valued at approximately $26,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Ovid Therapeutics by 22.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,396 shares of the company's stock valued at $54,000 after purchasing an additional 3,145 shares during the period. Jump Financial LLC bought a new stake in shares of Ovid Therapeutics during the 3rd quarter valued at about $61,000. BNP Paribas Financial Markets grew its stake in Ovid Therapeutics by 74.7% during the first quarter. BNP Paribas Financial Markets now owns 32,162 shares of the company's stock worth $98,000 after purchasing an additional 13,756 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Ovid Therapeutics in the third quarter valued at approximately $100,000. 72.24% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Ovid Therapeutics news, CEO Jeremy M. Levin purchased 18,248 shares of the company's stock in a transaction dated Monday, March 18th. The stock was purchased at an average price of $2.76 per share, with a total value of $50,364.48. Following the completion of the purchase, the chief executive officer now owns 3,616,715 shares of the company's stock, valued at $9,982,133.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 13.30% of the stock is currently owned by insiders.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.